Abstract
Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the UK, and is also approved in the USA and Canada for the treatment of major depressive episodes associated with bipolar I disorder as either a monotherapy or adjunctive therapy with lithium or valproate. In addition to full antagonist activity at dopamine D2 (Ki(D2) = 1 nM) and serotonin 5-HT2A (Ki(5-HT2A) = 0.5 nM) receptors, the pharmacodynamic profile of lurasidone is notable for its high affinity for serotonin 5-HT7 receptors (Ki(5-HT7) = 0.5 nM) and its partial agonist activity at 5-HT1A receptors (Ki(5-HT1A) = 6.4 nM). Long-term treatment of schizophrenia with lurasidone has been shown to reduce the risk of relapse. Lurasidone appears associated with minimal effects on body weight and low risk for clinically meaningful alterations in glucose, lipids or electrocardiogram parameters.
Highlights
Declaration of interest A.L. is a full-time employee of Sunovion Pharmaceuticals
In the European Medicines Agency Summary of Product Characteristics,[2] tablet strength refers to the weight of active drug only, excluding the contribution from the HCl salt (Table 1 shows the dose equivalence), and this dose convention will be used in the current review. The purpose of this overview is to describe the pharmacodynamics and pharmacokinetics of lurasidone, and to summarise its efficacy and safety for the treatment of schizophrenia and bipolar depression based on results from both short-term and longer-term controlled clinical trials
Adverse event frequencies reported in the bipolar depression programme, where lurasidone was dosed at night in all studies, were generally lower than observed in patients with schizophrenia.[1]
Summary
Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. Summary Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the UK, and is approved in the USA and Canada for the treatment of major depressive episodes associated with bipolar I disorder as either a monotherapy or adjunctive therapy with lithium or valproate. In the European Medicines Agency Summary of Product Characteristics,[2] tablet strength refers to the weight of active drug only, excluding the contribution from the HCl salt (Table 1 shows the dose equivalence), and this dose convention will be used in the current review The purpose of this overview is to describe the pharmacodynamics and pharmacokinetics of lurasidone, and to summarise its efficacy and safety for the treatment of schizophrenia and bipolar depression based on results from both short-term and longer-term controlled clinical trials. Relevant information regarding switching and extension studies is reported, including functional and cognitive outcomes
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
